» Articles » PMID: 22822048

Biomarkers of Aggressive Pituitary Adenomas

Overview
Date 2012 Jul 24
PMID 22822048
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Pituitary adenomas exhibit a wide range of behaviors. The prediction of aggressive or malignant behavior in pituitary adenomas remains challenging; however, the utility of biomarkers is rapidly evolving. In this review, we discuss potential biomarkers as they relate to aggressive behavior in pituitary adenomas. While detailed histological subtyping remains the best independent predictor of aggressive behavior in the majority of cases, evidence suggests that the additional analyses of FGFR4, MMP, PTTG, Ki-67, p53, and deletions in chromosome 11 may contribute to decisions concerning management of aggressive pituitary adenomas.

Citing Articles

Expression of MMP-2, MMP-9 and TIMP-2 in pituitary tumors and their relationship with cavernous sinus invasion.

The B Freire A, Jallad R, Batista R, Glezer A, Machado M, Ochman G Endocr Oncol. 2025; 5(1):e240037.

PMID: 39810846 PMC: 11728929. DOI: 10.1530/EO-24-0037.


Fibrous bodies in pituitary adenoma.

Shigihalli A, Kumar A, Sharma M, Balasubramanian A, Madakshira M Med J Armed Forces India. 2024; 80(Suppl 1):S430-S432.

PMID: 39734841 PMC: 11670709. DOI: 10.1016/j.mjafi.2024.02.005.


Chromosomal alteration patterns in PitNETs: massive losses in aggressive tumors.

Jentus M, Bakker L, Verstegen M, Pelsma I, van Wezel T, Ruano D Endocr Relat Cancer. 2024; 32(1.

PMID: 39441837 PMC: 11729050. DOI: 10.1530/ERC-24-0070.


KLHL14 and E-Cadherin Nuclear Co-Expression as Predicting Factor of Nonfunctioning PitNET Invasiveness: Preliminary Study.

Berardinelli J, Russo V, Canciello A, Di Giacinto O, Mauro A, Nardinocchi D J Clin Med. 2024; 13(15).

PMID: 39124679 PMC: 11312959. DOI: 10.3390/jcm13154409.


Developmental pluripotency-associated 4 increases aggressiveness of pituitary neuroendocrine tumors by enhancing cell stemness.

Chaudhary S, Das U, Jabbar S, Gangisetty O, Rousseau B, Hanft S Neuro Oncol. 2024; 27(1):123-139.

PMID: 39093695 PMC: 11726338. DOI: 10.1093/neuonc/noae148.